# PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

> **NCT03618030** · PHASE3 · COMPLETED · sponsor: **Purdue Pharma, Canada** · enrollment: 288 (actual)

## Conditions studied

- ADHD

## Interventions

- **DRUG:** PRC-063 oral capsules
- **DRUG:** Placebo oral capsules

## Key facts

- **NCT ID:** NCT03618030
- **Lead sponsor:** Purdue Pharma, Canada
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-21
- **Primary completion:** 2019-07-05
- **Final completion:** 2019-07-05
- **Target enrollment:** 288 (ACTUAL)
- **Last updated:** 2021-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03618030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03618030, "PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03618030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*